-
Halozyme Achieves Endpoint In Pancreatic Cancer Study, But Not Everyone Is Bullish
Thursday, January 5, 2017 - 10:56am | 505Read More...Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company focused on developing and commercializing novel oncology products that target tumor microenvironment, gained more than 10 percent Thursday morning. Investors and traders were buying Halozyme's stock after the company...
-
Neptune Pops And Drops After New Guidance
Tuesday, April 5, 2016 - 10:28am | 198Read More...Shares of Neptune Technologies & Bioressources (NASDAQ: NEPT), a biotechnology company that focuses on the development of marine-derived omega-3 polyunsaturated fatty acids (PUFAs), spiked by more than 5 percent before selling off. Neptune announced preliminary results for the fourth quarter...
